STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea
Status:
Completed
Trial end date:
2003-07-01
Target enrollment:
Participant gender:
Summary
Currently there is an ongoing clinical trial for patients with chemotherapy induced diarrhea.
This trial is being conducted to evaluate the efficacy of two dose levels (30 mg and 40 mg)
of an investigational drug in reducing the occurrence of severe (Grade 3 or 4) diarrhea
during chemotherapy. Eligible patients must either have experienced NCI Common Toxicity Grade
1 - 4 chemotherapy-induced diarrhea during previous chemotherapy treatment or be experiencing
Grade 1-4 chemotherapy-induced diarrhea currently.
In order to participate in this clinical trial, patients must be male or female 18 years of
age or older. Inclusion into this investigational drug trial is based on the protocol entry
criteria and a detailed evaluation from a participating trial investigator